Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

[Lamotrigine: monotherapy in refractory epilepsy]

F De Romanis¹, N Sopranzi

¹Dipartimento di Scienze Neurologiche, Università degli Studi di Roma La Sapienza.

La Clinica Terapeutica

|April 1, 1997

Summary

Carbamazepine (CBZ) plus lamotrigine (LTG) was tested in epilepsy patients. LTG monotherapy significantly reduced seizure frequency more effectively than the combination therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A sharp band resonance absorption filter.

Applied optics·2010

Same author

[Lamotrigine in the therapy of resistant epilepsy].

La Clinica terapeutica·1999

Same author

[Efficacy of vigabatrin associated with carbamazepine in the treatment of epilepsy. Follow up 1993-1996].

La Clinica terapeutica·1998

Same author

[Felbamate: a long-term study in subjects with refractory epilepsy].

La Clinica terapeutica·1997

Same author

[New antiepileptic drugs: a review and personal contribution].

La Clinica terapeutica·1996

Same author

[Lamotrigine: first experience in Italy].

La Clinica terapeutica·1995

Area of Science:

Neurology
Clinical Pharmacology

Background:

Refractory epilepsy poses significant treatment challenges.
Combination therapy with carbamazepine (CBZ) and lamotrigine (LTG) is used for partial seizures.

Purpose of the Study:

To compare the efficacy of LTG monotherapy versus combination therapy with CBZ + LTG in patients with refractory partial seizures.
To evaluate LTG as a single-drug therapy for treatment-resistant epilepsy.

Main Methods:

A trial involving 31 subjects with refractory partial complex and/or partial secondary generalized seizures.
Initial phase: administration of CBZ + LTG. Follow-up phase: LTG monotherapy at lower doses (125-250 mg).
Seizure frequency was monitored over an 8-12 month period.

Main Results:

LTG monotherapy resulted in an 82.2% reduction in total seizure frequency.
The combination of CBZ + LTG showed a 53.5% reduction in seizure frequency.
The difference in seizure reduction was highly significant (p < 0.0001) in favor of LTG monotherapy.

Conclusions:

Lamotrigine (LTG) monotherapy demonstrates superior efficacy in reducing seizure frequency compared to combination therapy with carbamazepine (CBZ) in patients with refractory partial epilepsy.
LTG monotherapy represents a significant improvement for therapy-resistant epilepsy.

Related Experiment Videos